Interaction Checker

Add peptides or compounds to check all pairwise interactions, cumulative organ load, and safety flags.

This stack has significant risks: 1 interaction(s) to avoid and 1 critical warning(s). Review carefully before proceeding.
1 combination(s) marked "avoid": Raloxifene + Tamoxifen. Review these interactions carefully.

Cumulative Organ Load

Gonads
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Raloxifene, Tamoxifen). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the pct-agent safety flag (Raloxifene, Tamoxifen). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (Raloxifene, Tamoxifen). Monitor accordingly.
!
Raloxifene + Tamoxifen
Avoid

Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery.

Researched 95% confidence Compare

Interaction data is compiled from research literature, pharmacological analysis, and community reports. Inferred interactions are based on known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.